Wu, F. et al. A new coronavirus associated with human respiratory disease in China. Nature 579, 265–269 (2020).
Wu, Z. & McGoogan, J. M. Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) in China. JAMA 323, 1239–1242 (2020).
Wichmann, D. et al. Autopsy findings and venous thromboembolism in patients with COVID-19. Ann. Intern. Med. https://doi.org/10.7326/M20-2003 (2020).
Hon, K. L. et al. Clinical presentations and outcome of severe acute respiratory syndrome in children. Lancet 361, 1701–1703 (2003).
Viner, R. M. & Whittaker, E. Kawasaki-like disease: emerging complication during the COVID-19 pandemic. Lancet 395, 1741–1743 (2020).
Marks, M. & Marks, J. L. Viral arthritis. Clin. Med. 16, 129–134 (2016).
Friedman, N. et al. Human coronavirus infections in Israel: epidemiology, clinical symptoms and summer seasonality of HCoV-HKU1. Viruses 10, 515 (2018).
Guan, W.-J. et al. Clinical characteristics of coronavirus disease 2019 in China. N. Engl. J. Med. 382, 1708–1720 (2020).
Christian, M. D., Poutanen, S. M., Loutfy, M. R., Muller, M. P. & Low, D. E. Severe acute respiratory syndrome. Clin. Infect. Dis. 38, 1420–1427 (2004).
Li, S. et al. Symptom combinations associated with outcome and therapeutic effects in a cohort of cases with SARS. Am. J. Chin. Med. 34, 937–947 (2006).
Memish, Z. A., Perlman, S., Van Kerkhove, M. D. & Zumla, A. Middle East respiratory syndrome. Lancet 395, 1063–1077 (2020).
Russel, C. D. et al. Clinical evidence does not support corticosteroid treatment for 2019-nCoV lung injury. Lancet 395, 473–475 (2020).
Peiris, J. S. M. et al. Clinical progression and viral load in a community outbreak of coronavirus-associated SARS pneumonia: a prospective study. Lancet 361, 1767–1772 (2003).
Stockman, L. J., Bellamy, R. & Garner, P. SARS: systematic review of treatment effects. PLoS Med. 3, e343 (2006).
Joo, Y. B., Lim, Y.-H., Kim, K.-J., Park, K.-S. & Park, Y.-J. Respiratory viral infections and the risk of rheumatoid arthritis. Arthritis Res. Ther. 21, 199 (2019).
Hoffmann, M. et al. SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor. Cell 181, 271–280.e8 (2020).
Pedersen, K. B. et al. Dynamics of ADAM17-mediated shedding of ACE2 applied to pancreatic islets of male db/db mice. Endocrinology 156, 4411–4425 (2015).
Liu, J. et al. Overlapping and discrete aspects of the pathology and pathogenesis of the emerging human pathogenic coronaviruses SARS-CoV, MERS-CoV, and 2019-nCoV. J. Med. Virol. 92, 491–494 (2020).
Katsura, H. et al. IL-1 and TNFα contribute to the inflammatory niche to enhance alveolar regeneration. Stem Cell Rep. 12, 657–666 (2019).
Starr, M. et al. Age-associated increase in cytokine production during systemic inflammation — II: the role of IL-1β in age-dependent IL-6 upregulation in adipose tissue. J. Gerontol. 70, 1508–1515 (2015).
Angelidis, I. et al. An atlas of the aging lung mapped by single cell transcriptomics and deep tissue proteomics. Nat. Commun. 10, 963 (2019).
Huang, C. et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet 395, 497–506 (2020).
Schett, G., Sticherling, M. & Neurath, M. F. COVID-19: risk for cytokine targeting in chronic inflammatory diseases? Nat. Rev. Immunol. 20, 271–272 (2020).
Yoshikawa, T. et al. Severe acute respiratory syndrome (SARS) coronavirus-induced lung epithelial cytokines exacerbate SARS pathogenesis by modulating intrinsic functions of monocyte-derived macrophages and dendritic cells. J. Virol. 83, 3039–3048 (2009).
Zhang, X. et al. Nucleocapsid protein of SARS-CoV activates interleukin-6 expression through cellular transcription factor NF-κB. Virology 365, 324–335 (2007).
Law, H. K. et al. Chemokine up-regulation in SARS-coronavirus-infected, monocyte-derived human dendritic cells. Blood 106, 2366–2374 (2005).
Josset, L. et al. Cell host response to infection with novel human coronavirus EMC predicts potential antivirals and important differences with SARS coronavirus. mBio 4, e00165-13 (2013).
Ryzhakov, G. et al. IL-17 boosts proinflammatory outcome of antiviral response in human cells. J. Immunol. 187, 5357–5362 (2011).
Rauber, S. et al. Resolution of inflammation by interleukin-9-producing type 2 innate lymphoid cells. Nat. Med. 23, 938–944 (2017).
Chen, Z. et al. TH2 and eosinophil responses suppress inflammatory arthritis. Nat. Commun. 7, 11596 (2016).
Sarzi-Puttini, P. et al. COVID-19, cytokines and immunosuppression: what can we learn from severe acute respiratory syndrome? Clin. Exp. Rheumatol. 38, 337–342 (2020).
Henderson, L. A. et al. On the alert for cytokine storm: immunopathology in COVID-19. Arthritis Rheumatol. https://doi.org/10.1002/art.41285 (2020).
Stebbing, J. et al. COVID-19: combining antiviral and anti-inflammatory treatments. Lancet Infect. Dis. 20, 400–402 (2020).
Channappanavar, R. & Perlman, S. Pathogenic human coronavirus infections: causes and consequences of cytokine storm and immunopathology. Semin. Immunopathol. 39, 529–539 (2017).
Pedersen, S. F. & Ho, Y. C. SARS-CoV-2: a storm is raging. J. Clin. Invest. 130, 2202–2205 (2020).
Xu, X. et al. Effective treatment of severe COVID-19 patients with tocilizumab. Proc. Natl Acad. Sci. USA 117, 10970–10975 (2020).
US National Library of Medicine. ClinicalTrials.gov https://clinicaltrials.gov/ct2/show/NCT04380961 (2020).
US National Library of Medicine. ClinicalTrials.gov https://www.clinicaltrials.gov/ct2/show/NCT04324021 (2020).
US National Library of Medicine. ClinicalTrials.gov https://www.clinicaltrials.gov/ct2/show/NCT04348448 (2020).
Qian, Y. et al. Innate immune response of human alveolar type II cells infected with severe acute respiratory syndrome–coronavirus. Am. J. Respir. Cell Mol. Biol. 48, 742–748 (2013).
Tobinick, E. TNF-α inhibition for potential therapeutic modulation of SARS coronavirus infection. Curr. Med. Res. Opin. 20, 39–40 (2004).
Feldmann, M. et al. Trials of anti-tumour necrosis factor therapy for COVID-19 are urgently needed. Lancet 395, 1407–1409 (2020).
Hussell, T., Pennycook, A. & Openshaw, P. J. Inhibition of tumor necrosis factor reduces the severity of virus-specific lung immunopathology. Eur. J. Immunol. 31, 2566–2573 (2001).
Monti, S. et al. Clinical course of COVID-19 in a series of patients with chronic arthritis treated with immunosuppressive targeted therapies. Ann. Rheum. Dis. 79, 667–668 (2020).
Chinese Clinical Trial Registry. ChiCTR.org http://www.chictr.org.cn/showprojen.aspx?proj=49889 (2020).
Lu, R. et al. Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding. Lancet 395, 565–574 (2020).
Richardson, P. et al. Baricitinib as potential treatment for 2019-nCoV acute respiratory disease. Lancet 395, e30–e31 (2020).
US Department of Health and Human Services. Coronavirus (COVID-19). NIH.gov https://www.nih.gov/health-information/coronavirus (2020).
Codarri, L. et al. RORγt drives production of the cytokine GM-CSF in helper T cells, which is essential for the effector phase of autoimmune neuroinflammation. Nat. Immunol. 12, 560–567 (2011).
US National Library of Medicine. ClinicalTrials.gov https://clinicaltrials.gov/ct2/show/NCT04341116 (2020).
Blumentals, W. A. et al. Rheumatoid arthritis and the incidence of influenza and influenza-related complications: a retrospective cohort study. BMC Musculoskelet. Disord. 13, 158 (2012).
An, P. et al. Protection of 318 inflammatory bowel disease patients from the outbreak and rapid spread of COVID-19 infection in Wuhan, China. https://ssrn.com/abstract=3543590 (Social Science Research Network, 2020).
Norsa, L. et al. Uneventful course in IBD patients during SARS-CoV-2 outbreak in northern Italy. Gastroenterology https://doi.org/10.1053/j.gastro.2020.03.062 (2020).
Velazquez-Salinas, L. et al. The role of interleukin-6 during viral infection. Front. Microbiol. 10, 1057 (2019).
Fleming, S. Viral inhibition of the IFN-induced JAK/STAT signalling pathway: development of live attenuated vaccines by mutation of viral-encoded IFN-antagonists. Vaccines 4, 23 (2016).
Bechman, K. et al. A systematic review and meta-analysis of infection risk with small molecule JAK inhibitors in rheumatoid arthritis. Rheumatology 58, 1755–1766 (2019).
Kelesidis, T., Mastoris, I., Metsini, A. & Tsiodras, S. How to approach and treat viral infections in ICU patients. BMC Infect. Dis. 14, 321 (2014).
Tan, L. et al. Lymphopenia predicts disease severity of COVID-19: a descriptive and predictive study. Signal. Transduct. Targ. Ther. 5, 33 (2020).
Favalli, E. G., Biggioggero, M., Maioli, G. & Caporali, R. Baricitinib for COVID-19: a suitable treatment? Lancet Infect. Dis. https://doi.org/10.1016/S1473-3099(20)30262-0 (2020).
Praveen, D., Chowdary, P. R. & Aanandhi, M. V. Baricitinib, a Janus kinase inhibitor, not an ideal option for management of COVID 19. Int. J. Antimicrob. Agents 55, 105967 (2020).
Thanh, Le. T. et al. The COVID-19 vaccine development landscape. Nat. Rev. Drug Discov. 19, 305–306 (2020).
Meroni, P. L., Zavaglia, D. & Girmenia, C. Vaccinations in adults with rheumatoid arthritis in an era of new disease-modifying anti-rheumatic drugs. Clin. Exp. Rheumatol. 36, 317–328 (2018).
Marotto, D. & Sarzi-Puttini, P. What is the role of rheumatologists in the era of COVID-19? Autoimmun. Rev. 19, 102539 (2020).
Hollander, J. E. & Sites, F. D. The transition from reimagining to recreating health care is now. NEJM Catalyst https://doi.org/10.1056/CAT.20.0093 (2020).
Spinelli, F. R., Ceccarelli, F., Di Franco, M. & Conti, F. To consider or not antimalarials as a prophylactic intervention in the SARS-CoV-2 (Covid-19) pandemic. Ann. Rheum. Dis. 79, 666–667 (2020).
European Medicines Agency. COVID-19: chloroquine and hydroxychloroquine only to be used in clinical trials or emergency use programmes. EMA.europa.EU https://www.ema.europa.eu/en/news/covid-19-chloroquine-hydroxychloroquine-only-be-used-clinical-trials-emergency-use-programmes (2020).